https://www.selleckchem.com/pr....oducts/mk-5108-vx-68
Improved clinical responses were seen at v2 [ASDAS-CRP -0.41(-0.81-0.3, p= 0.018; BASDAI -0.58(-2.2-0.52), p= 0.024]. Despite just a 4-day interval between v1 and v2, a numerical reduction in MRI-BMO lesions between v1/v2 was observed (ETA=-6, ADA=-10, IFX=-3). By v3 comparatively fewer new BMO lesions were detected in the ETA and ADA groups compared with IFX (ETA=-1, ADA = +3, IFX = +8), although the numbers were too small to enable testing for statistical significance. Short-lived fluctuations in MRI-BMO were commoner with lo
Like
Comment
Share
